Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : EPPH ; Epoch Pharmaceuticals, Bothell WA -- Ignore unavailable to you. Want to Upgrade?

To: priceguy who wrote (6)	1/11/1999 11:20:00 AM
From: GARY P GROBBEL	Read Replies (1) \| Respond to of 11

EPPH/Perkins-Elmer...wake up thread<g>. This press release came out this morning...stock up .06 to .65 on 28,000 as of 11.15a. Epoch files w/the SEC and profile avail on Yahoo...52wh .93/52wl .45...do your own DD: PE Biosystems Enters Into License, Manufacturing and Supply Agreement With Epoch Pharmaceuticals, Inc. Epoch's Proprietary Genetic Analysis Technology Increases Efficiency Of Perkin-Elmer Research Probes REDMOND, Wash., Jan. 11 /PRNewswire/ -- Epoch Pharmaceuticals, Inc. (OTC Bulletin Board: EPPH - news) announced today that it has licensed certain of its enabling genetic analysis technology to the PE Biosystems Division of The Perkin-Elmer Corporation. As part of the agreement, Perkin-Elmer will be purchasing Epoch's proprietary chemical intermediates. The license fields are for applications pertaining to Perkin-Elmer's proprietary technology in the areas of biomedical research and certain non-clinical applied fields. In addition to the up-front license fees and pre-payments for future purchases, Epoch shall receive a royalty on all products that Perkin-Elmer sells which incorporate the technology. Epoch has recently discovered that the compounds and techniques that were being developed for its gene modification therapeutic program can be broadly enabling and are adaptable to several gene sequencing analysis systems currently in use or being developed by others. The Company believes that this technology has significant commercial applications in the fields of molecular diagnostics and genomics, including the detection of infectious diseases, inheritable diseases through prenatal testing, screening populations to identify genetic markers that correlate with disease risk or drug response, as well as any other genetic analysis based on DNA sequence determination. ''This transaction brings outside validation to the technology which has been developed under the redirected research efforts at Epoch,'' said Fred Craves, Ph.D., the Chairman and CEO of Epoch. ''We believe this transaction is a major step in the turnaround of Epoch into a sustainable R&D and manufacturing company with attractive growth potential.'' This press release contains forward-looking statements concerning the Company's research and development activities. Actual results may differ materially, depending on a number of risk factors. As discussed in the Company's Securities and Exchange Commission filings, these risks include the possibility that the potential products utilizing the Company's technology may at any time be found to be ineffective or although effective, may be uneconomical to market, or that third parties hold proprietary rights that preclude Epoch from marketing them, or that third parties market a superior or equivalent product. The Company will need significant additional financial resources to complete its research activities and there are no assurances that such resources will be available in a timely or acceptable manner, or at all. SOURCE: Epoch Pharmaceuticals, Inc.